W

Lilly raises outlook for third time this year as Zepbound sales soar

Business Management
Share
Lilly raises outlook for third time this year as Zepbound sales soar

The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.

Lilly raises outlook for third time this year as Zepbound sales soar

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

DoorDash and Instacart want to join forces. Will the U.S. government get in their way?

The companies say their proposed merger will help smaller grocers compete, but analysts wonder if regulators will conduct an “extended review” of antitrust…

A new framework for tokenized asset tracking

None of the numbers most commonly used to assess tokenized assets answer the question a chief investment officer would ask about those assets on her own…

Tokenized stock venue on Canton could beat OKX–ICE to first trade under SEC framework

The venue, called TSV LLC, plans to start trading shares Canton Strategic Holdings shares as early as Monday, using issuersponsored tokenization that avoids…

Chainalysis traces North Korean crypto cash-outs through Garantex

The analysis followed US sanctions against 10 people and one entity accused of helping North Korean IT worker schemes fund weapons programs.…

Source：https://www.marketwatch.com/story/lilly-raises-outlook-for-third-time-this-year-as-zepbound-sales-soar-6d987407